Clinical Implications of Glyoxalase1 Gene Polymorphism and Elevated Levels of the Reactive Metabolite Methylglyoxal in the Susceptibility of Type 2 Diabetes Mellitus in the Patients from Asir and Tabuk Regions of Saudi Arabia.
GLO1-glyoxalase-1
T2DM
methylglyoxal
rs1130534 T>A
rs2736654 C>A
single nucleotide polymorphism
type 2 diabetes in Saudi Arabia
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
15 Apr 2022
15 Apr 2022
Historique:
received:
29
01
2022
revised:
07
03
2022
accepted:
08
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Diabetes mellitus constitutes a big challenge to the global health care system due to its socioeconomic impacts and very serious complications. The incidence and the prevalence rate are increased in the Gulf region including the KSA. Type 2 diabetes mellitus (T2DM) is caused by diverse risk factors including obesity, unhealthy dietary habits, physical inactivity, smoking and genetic factors. The molecular genetic studies have helped in the detection of many single nucleotide polymorphisms (SNP) with different diseases including cancers, cardiovascular diseases and T2DM. The glyoxalase 1 (GLO1) is a detoxifying enzyme and catalyzes the elimination of the cytotoxic product methylglyoxal (MG) by converting it to D-lactate, which is not toxic to tissues. MG accumulation is associated with the pathogenesis of different diseases including T2DM. In this study, we have investigated the association of the glyoxalase 1 SNPs (rs2736654) rs4746 C>A and rs1130534 T>A with T2DM using the amplification refractory mutation system PCR. We also measured the concentration of MG by ELISA in T2DM patients and matched heathy controls. Results show that the CA genotype of the GLO rs4647 A>C was associated with T2DM with OR = 2.57, p-value 0.0008 and the C allele was also associated with increased risk to T2DM with OR = 2.24, p-value = 0.0001. It was also observed that AT genotype of the rs1130534 was associated with decreased susceptibility to T2DM with OR = 0.3, p-value = 0.02. The A allele of rs1130534 was also associated with reduced risk to T2DM with PR = 0.27 = 0.006. In addition, our ELISA results demonstrate significantly increased MG concentrations in serum of the T2DM patients. We conclude that the GLO1 SNP may be associated with decreased enzyme activity and a resultant susceptibility to T2DM. Further well-designed studies in different and large patient populations are recommended to verify these findings.
Identifiants
pubmed: 35455754
pii: jpm12040639
doi: 10.3390/jpm12040639
pmc: PMC9030104
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : "Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia
ID : 49/1442
Références
Mol Carcinog. 2017 Sep;56(9):2112-2126
pubmed: 28470764
Arthritis Res Ther. 2019 Jan 11;21(1):18
pubmed: 30635030
Exp Suppl. 2019;111:385-416
pubmed: 31588541
Sci Rep. 2017 May 10;7(1):1698
pubmed: 28490763
Int J Environ Res Public Health. 2019 Dec 18;17(1):
pubmed: 31861311
Biochem J. 2013 Jul 1;453(1):1-15
pubmed: 23763312
Diabetes. 2006 May;55(5):1289-99
pubmed: 16644685
Pharmacol Res. 2020 Nov;161:105198
pubmed: 32942016
Amino Acids. 2012 Apr;42(4):1133-42
pubmed: 20963454
Int J Mol Sci. 2020 Aug 30;21(17):
pubmed: 32872570
Br J Psychiatry. 2011 Sep;199(3):245-6
pubmed: 21881099
Am J Med Genet A. 2004 Nov 15;131(1):11-7
pubmed: 15386471
J Epidemiol Glob Health. 2017 Dec;7(4):211-218
pubmed: 29110860
Front Endocrinol (Lausanne). 2013 Mar 27;4:37
pubmed: 23542897
PLoS One. 2010 Apr 29;5(4):e10399
pubmed: 20454679
Biol Open. 2014 Jul 25;3(8):777-84
pubmed: 25063200
Semin Cell Dev Biol. 2011 May;22(3):293-301
pubmed: 21320620
Data Brief. 2017 Dec 13;16:929-938
pubmed: 29511711
Drug Metabol Drug Interact. 2008;23(1-2):13-27
pubmed: 18533362
Gene. 2013 Feb 15;515(1):140-3
pubmed: 23201419
Can J Physiol Pharmacol. 2006 Dec;84(12):1229-38
pubmed: 17487230
Oncol Res Treat. 2014;37(10):570-4
pubmed: 25342507
J Endocrinol Invest. 2011 Nov;34(10):e343-8
pubmed: 21738003
Korean J Physiol Pharmacol. 2014 Feb;18(1):1-14
pubmed: 24634591
Biochem Soc Trans. 2014 Apr;42(2):433-8
pubmed: 24646256
Diabetes. 2017 Aug;66(8):2278-2283
pubmed: 28588100
Semin Cell Dev Biol. 2011 May;22(3):309-17
pubmed: 21335095
Cell Rep. 2020 Sep 22;32(12):108160
pubmed: 32966793
Antioxidants (Basel). 2021 Feb 22;10(2):
pubmed: 33671767
Physiol Rev. 2020 Jan 1;100(1):407-461
pubmed: 31539311
Diabetes Care. 2009 Jan;32 Suppl 1:S62-7
pubmed: 19118289
Science. 2007 Jun 1;316(5829):1331-6
pubmed: 17463246
Biomed Pharmacother. 2020 Nov;131:110663
pubmed: 32858501
Semin Cell Dev Biol. 2011 May;22(3):318-25
pubmed: 21315826
Semin Cancer Biol. 2018 Apr;49:83-93
pubmed: 28506645
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):949-54
pubmed: 11792832
Antioxidants (Basel). 2019 Jan 17;8(1):
pubmed: 30658464
Nucleic Acids Res. 2010 Sep;38(16):5432-42
pubmed: 20435681
Am J Pathol. 2018 Nov;188(11):2553-2563
pubmed: 30125541
Front Mol Neurosci. 2021 Nov 01;14:739526
pubmed: 34790095
Arch Gen Psychiatry. 2010 Jun;67(6):589-97
pubmed: 20530008
Antioxid Redox Signal. 2019 Jan 20;30(3):354-374
pubmed: 29160087
Antioxidants (Basel). 2021 Feb 02;10(2):
pubmed: 33540757
Clin Sci (Lond). 2015 Jun;128(12):839-61
pubmed: 25818485
Eur J Biochem. 1993 Feb 15;212(1):101-5
pubmed: 8444148
Autism Res. 2011 Aug;4(4):262-70
pubmed: 21491613
Physiol Rev. 2013 Jan;93(1):137-88
pubmed: 23303908